X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.biospace.com/article/novartis-canakinumab-continues-losing-streak-with-phase-iii-nsclc-flop/
https://www.fiercepharma.com/pharma/novartis-looks-for-silver-lining-2b-ilaris-canakinumab-repurposing-2nd-lung-cancer-failure
https://pharmaphorum.com/news/strike-two-for-novartis-lung-cancer-antibody-canakinumab/
https://www.globenewswire.com/news-release/2021/10/25/2319489/0/en/Novartis-top-line-results-for-CANOPY-1-Phase-III-study-support-further-evaluation-of-canakinumab-in-lung-cancer.html
https://www.biopharmadive.com/news/novartis-canakinumab-lung-cancer-study-results-negative/608820/
https://www.reuters.com/article/us-novartis-canakinumab-idUSKBN2B10HC
http://www.pharmafile.com/news/563267/novartis-arthritis-therapy-shows-no-efficacy-hospitalised-covid-19-patients
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125319
https://www.fiercebiotech.com/research/novartis-ilaris-unexpectedly-slashes-need-for-joint-replacements-from-osteoarthritis-key
https://www.fiercebiotech.com/research/novartis-ilaris-unexpectedly-slashes-need-for-joint-replacements-from-osteoarthritis-key
http://www.pmlive.com/pharma_news/novartis_nabs_new_fda_approvals_for_ilaris_and_cosentyx_1342490
http://www.pharmatimes.com/news/novartis_ilaris_first_drug_approved_for_stills_disease_1342435
https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-adult-onset-stills-disease-severe-and-rare-disease#:~:text=The%20U.S.%20Food%20and%20Drug,aged%202%20years%20and%20older.
https://www.fiercepharma.com/pharma/after-hydroxychloroquine-and-jakafi-novartis-plans-covid-19-testing-for-ilaris
https://endpts.com/once-again-novartis-cardio-team-looks-to-beat-the-odds-using-sketchy-data-and-a-familiar-argument/
https://endpts.com/the-top-10-pipeline-blowups-setbacks-and-snafus-for-h2-2018/
http://www.pharmatimes.com/news/novartis_pulls_eu_filing_for_canakinumab_1272906
https://www.fiercebiotech.com/biotech/inflazome-brings-new-cmo-after-eu40m-vc-round
Market Place
Share 
